US5214036A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Benzoporphyrin derivatives for photodynamic therapy
Assignee: University of British Columbia
•
Filing: 1990-03-08
•
Granted: 1993-05-25
•
Expires: 2010-03-08
Abstract
Abstract Green porphyrins (Gp), compounds important in photodynamic therapy, have been associated with lipocomplexes to reduce the required amount of photosensitizer through higher effective absorption and increased specificity. BPDs, especially in conjunction with the HDL fraction of plasma lipoproteins, has been shown to be particularly effective in this context. Pharmaceutical compositions in which these combinations are the active ingredients for use in diagnosis and treatment of tumors are also disclosed.
Inventors
- 👤 Beth A. Allison
- 👤 Anna M. Richter
- 👤 P. Haydn Pritchard
- 👤 Julia G. Levy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:51
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071; A61K31/00; A61K31/33; A61K31/395; A61K31/40
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
154 words
A pharmaceutical composition for photodynamic therapy comprising: a green porphyrin compound having a formula selected from the group consisting of ##STR4## wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, carbalkoxy (2-6 C), alkyl (1-6 C) sulfonyl, aryl (6-10 C) sulfonyl, aryl (6-10 C), and cyano, further wherein at least one of R 1 and R 2 is not hydrogen; each R 3 is independently selected from the group consisting of alkyl (1-6 C), carboxyalkyl (2-6 C) and salts and esters thereof; and R 4 is selected from the group consisting of --CH═CH 2 , --CH 2 OR', --CHO, --COOR', --CH(OR')CH 3 , --CH(OR')CH 2 OR', --CH(SR')CH 3 , --CH(NR' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR')CH 3 , --CH(OOCR')CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein each R' is hydrogen or alkyl (1-6 C); a lipocomplex; and a pharmaceutically acceptable injectable carrier solution.
Claim 2
Dependent Claim
154 words
A pharmaceutical composition for photodynamic therapy comprising: a green porphyrin compound having a formula selected from the group consisting of ##STR4## wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, carbalkoxy (2-6 C), alkyl (1-6 C) sulfonyl, aryl (6-10 C) sulfonyl, aryl (6-10 C), and cyano, further wherein at least one of R 1 and R 2 is not hydrogen; each R 3 is independently selected from the group consisting of alkyl (1-6 C), carboxyalkyl (2-6 C) and salts and esters thereof; and R 4 is selected from the group consisting of --CH═CH 2 , --CH 2 OR', --CHO, --COOR', --CH(OR')CH 3 , --CH(OR')CH 2 OR', --CH(SR')CH 3 , --CH(NR' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR')CH 3 , --CH(OOCR')CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein each R' is hydrogen or alkyl (1-6 C); a lipocomplex; and a pharmaceutically acceptable injectable carrier solution.
Claim 3
Dependent Claim
11 words
A composition of claim 1 wherein the green porphyrin is BPD-DA.
Claim 4
Dependent Claim
11 words
A composition of claim 1 wherein the green porphyrin is BPD-MA.
Claim 5
Dependent Claim
19 words
A composition of claim 1 wherein the lipocomplex is a lipoprotein mixture including HDL's, LDL's, VLDL's or combinations thereof.
Claim 6
Dependent Claim
13 words
The composition of claim 4 wherein the lipoprotein mixture consists essentially of HDL's.
Claim 7
Dependent Claim
13 words
The composition of claim 4 wherein the lipoprotein mixture consists essentially of LDL's.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-24 | 1996-11-23 | 1997-05-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-24 | 2000-11-23 | 2001-05-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-24 | 2004-11-23 | 2005-05-25 | $7700.00 | Window Closed / Lapsed |